Amiodarone or an Implantable Cardioverter–Defibrillator for Congestive Heart Failure

20056,497 citationsJournal Articlebronze Open Access

Authors

Gust H. Bardy · The Seattle Institute for Cardiac Research

Kerry L. Lee · Duke University

Daniel B. Mark · Duke University

Jeanne E. Poole · University of Washington

Douglas L. Packer · Mayo Clinic in Arizona

Robin Boineau · National Heart Lung and Blood Institute

Michaël Domanski

Abstract

In patients with NYHA class II or III CHF and LVEF of 35 percent or less, amiodarone has no favorable effect on survival, whereas single-lead, shock-only ICD therapy reduces overall mortality by 23 percent.

Topics & Keywords

Cardiac pacing and defibrillation studies Cardiac electrophysiology and arrhythmias Cardiac Arrhythmias and Treatments

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 352, Issue 3, pp. 225-237

DOI: 10.1056/nejmoa043399

Field-Weighted Citation Impact: 260.67